Cargando…

Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B

BACKGROUND: Ropeginterferon alfa-2b is a novel mono-pegylated interferon that has only one major form as opposed to 8–14 isomers of other on-market pegylated interferon, allowing injection every two or more weeks with higher tolerability. It received European Medicines Agency and Taiwan marketing au...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Yi-Wen, Hsu, Chao-Wei, Lu, Sheng-Nan, Yu, Ming-Lung, Su, Chien-Wei, Su, Wei-Wen, Chien, Rong-Nan, Hsu, Ching-Sheng, Hsu, Shih-Jer, Lai, Hsueh-Chou, Qin, Albert, Tseng, Kuan-Chiao, Chen, Pei-Jer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer India 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7803873/ https://www.ncbi.nlm.nih.gov/pubmed/33099752 http://dx.doi.org/10.1007/s12072-020-10098-y

Ejemplares similares

Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021)

A Case Report of Ropeginterferon Alfa-2b for Polycythemia Vera during Pregnancy
por: Bang, Su-Yeon, et al.
Publicado: (2023)

Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020)

Population Pharmacokinetics of Ropeginterferon Alfa-2b: A Comparison Between Healthy Caucasian and Chinese Subjects
por: Zhu, Min, et al.
Publicado: (2021)

Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023)

Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)

Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
por: Chen, Kuan-Yuan, et al.
Publicado: (2021)

Immunomodulatory and direct activities of ropeginterferon alfa‐2b on cancer cells in mouse models of leukemia
por: Sakatoku, Kazuki, et al.
Publicado: (2022)

Real world experience with ropeginterferon alpha-2b (Besremi) in essential thrombocythaemia and polycythaemia vera following exposure to pegylated interferon alfa-2a (Pegasys)
por: Okikiolu, Jumoke, et al.
Publicado: (2022)

Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment
por: Gisslinger, Heinz, et al.
Publicado: (2023)

Association of SCARB1 Gene Polymorphisms with Virological Response in Chronic Hepatitis C Patients Receiving Pegylated Interferon plus Ribavirin Therapy
por: Hsu, Ching-Sheng, et al.
Publicado: (2016)

A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera
por: Jin, Jie, et al.
Publicado: (2023)

An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future
por: Qin, Albert, et al.
Publicado: (2023)

P1007: PHASE 2, OPEN-LABEL, MULTICENTER, SINGLE-ARM STUDY INVESTIGATING THE EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B IN JAPANESE PATIENTS WITH POLYCYTHEMIA VERA
por: Kirito, K., et al.
Publicado: (2022)

S211: EFFICACY AND SAFETY OF ROPEGINTERFERON ALFA-2B FOR PRE-FIBROTIC PRIMARY MYELOFIBROSIS AND DIPSS LOW/INTERMEDIATE-1 RISK MYELOFIBROSIS: UPDATED RESULTS AND GENOMIC CHARACTERISTICS
por: Gill, Harry, et al.
Publicado: (2023)

P1042: COMPARISON OF THE RESPONSE TO ROPEGINTERFERON ALFA-2B IN HYDROXYUREA NAÏVE VERSUS RESISTANCE/INTOLERANCE POLYCYTHEMIA VERA: THE KOREAN SINGLE-ARM, OPEN-LABEL MULTICENTER STUDY
por: Lee, Sung-Eun, et al.
Publicado: (2023)

HBcrAg Identifies Patients Failing to Achieve HBeAg Seroconversion Treated with Pegylated Interferon Alfa-2b
por: Ma, Hui, et al.
Publicado: (2016)

Rapid Prediction of Treatment Futility of Boceprevir with Peginterferon-Ribavirin for Taiwanese Treatment Experienced Hepatitis C Virus Genotype 1-Infected Patients
por: Yang, Chi-Chieh, et al.
Publicado: (2015)

UGT2B28 genomic variation is associated with hepatitis B e-antigen seroconversion in response to antiviral therapy
por: Liang, Kung-Hao, et al.
Publicado: (2016)

Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo
por: Verger, Emmanuelle, et al.
Publicado: (2018)

Impact of Pegylated Interferon-alfa-2a on Perforin Level in Patients With Chronic Hepatitis B; Preliminary Study
por: Mahdavi, Meisam, et al.
Publicado: (2013)

Prior Therapy With Pegylated-Interferon Alfa-2b Improves the Efficacy of Adjuvant Pembrolizumab in Resectable Advanced Melanoma
por: Jia, Dong-Dong, et al.
Publicado: (2021)

The effects of high impact exercise intervention on bone mineral density, physical fitness, and quality of life in postmenopausal women with osteopenia: A retrospective cohort study
por: Yu, Pei-An, et al.
Publicado: (2019)

The Efficacy of Add-on Telbivudine Versus Switching to Pegylated Interferon Alfa-2a in Chronic Hepatitis B Patients With Poor Responses to Adefovir
por: Wei, Xin, et al.
Publicado: (2016)

Influences of cardiac motion on computed tomography-guided biopsy of lung nodules located near the heart
por: Hsu, Li-Sheng, et al.
Publicado: (2017)

Comparison of computer-assisted navigation and conventional instrumentation for bilateral total knee arthroplasty: The outcomes at mid-term follow-up
por: Hsu, Robert Wen-Wei, et al.
Publicado: (2019)

One-year efficacy of tenofovir alafenamide in patients with chronic hepatitis B: An observational study
por: Chen, Yi-Cheng, et al.
Publicado: (2022)

Early optic neuropathy during pegylated alfa 2-B interferon and ribavirin HCV treatment. A case report
por: Chis, Bogdan Augustin, et al.
Publicado: (2019)

Association of Statin and Its Lipophilicity With Cardiovascular Events in Patients Receiving Chronic Dialysis
por: Wang, Shih‐Wei, et al.
Publicado: (2019)

Interleukin-1 receptor antagonist gene polymorphism in patients with multidrug-resistant Acinetobacter baumannii-associated pneumonia
por: Hsu, Min-Jer, et al.
Publicado: (2012)

Quantification of serum hepatitis B surface antigen in predicting the response of pegylated interferon alfa-2a in HBeAg-positive chronic hepatitis B with prior lamivudine exposure
por: Weng, Min, et al.
Publicado: (2013)

Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis
por: Huang, Yi-Wen, et al.
Publicado: (2022)

P999: ROLE OF GENETIC VARIANTS IN PREDICTING EFFICACY AND/OR ADVERSE EVENTS OF ROPEGINTERFERON ALPHA-2B IN MPN PATIENTS: A RETROSPECTIVE ANALYSIS FROM AN ASIAN COHORT
por: Chen, Chih-Cheng, et al.
Publicado: (2023)

Sodium glucose cotransporter‐2 inhibitor was associated with an improvement in left ventricular systolic function in patients with type 2 diabetes mellitus with impaired left ventricular systolic function
por: Chan, Yi‐Hsin, et al.
Publicado: (2020)

Glossogyne tenuifolia Extract Inhibits TNF-α-Induced Expression of Adhesion Molecules in Human Umbilical Vein Endothelial Cells via Blocking the NF-κB Signaling Pathway
por: Hsuan, Chin-Feng, et al.
Publicado: (2015)

The Prenatal Diagnosis and Clinical Outcomes of Fetuses With 15q11.2 Copy Number Variants: A Case Series of 36 Patients
por: Kang, Jessica, et al.
Publicado: (2021)

Unbranched rod-like RNA is required for RNA editing of hepatitis delta virus genotype 2 and genotype 4
por: Hsu, Chao-Wei, et al.
Publicado: (2023)

Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
por: Tseng, Wei-Lung, et al.
Publicado: (2017)

Changes of ECG parameters after BNT162b2 vaccine in the senior high school students
por: Chiu, Shuenn-Nan, et al.
Publicado: (2023)

Effects of vitamin B-6 supplementation on oxidative stress and inflammatory response in neonatal rats receiving hyperoxia therapy
por: Lee, Ming-Sheng, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_eq3a7pejoo31mal4amdd3kv986